EMG
CBAY

ETF Managers Group’s Cymabay Therapeutics CBAY Stock Holding History

ETF Managers Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-34,899
Closed -$325K – 626
2018
Q2 		$325K Buy
+34,899
New +$437K 0.02% 184

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ETF Managers Group's CBAY Position: Q3 2018 in Review

ETF Managers Group sold out of Cymabay Therapeutics (CBAY) in Q3 2018, closing a stake of 34,899 shares — an estimated $325K sold.

ETF Managers Group first reported a position in CBAY in Q2 2018 and held it in 1 quarter. The position peaked at $325K in Q2 2018. 132 funds tracked by Wall St. Rank hold CBAY as of Q3 2018.

  • ETF Managers Group reported no remaining Cymabay Therapeutics position as of Q3 2018 after selling out during the quarter.
  • ETF Managers Group sold 34,899 Cymabay Therapeutics shares in Q3 2018, an estimated $325K.
  • ETF Managers Group first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 1 quarter.
  • ETF Managers Group's Cymabay Therapeutics position peaked at $325K in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2018.

Based on ETF Managers Group's 13F filing for Q3 2018, filed 14 Nov 2018.